Abstract 1753P
Background
In up to 30% of gastrointestinal (GI) malignancies, fluoropyrimidines (FP) are associated with severe adverse drug reactions (ADRs). Dihydropyrimidine dehydrogenase (DPYD), is a polymorphic gene involved in FP catabolism. The identification of deleterious variants associated with increased toxicity is recommended before treatment initiation [c.1905+1G>A (*2A); c.1679T>G (*13); c.1129-5923C>G (*IVS10); c.2846A>T (*949) or during treatment in case of ADR [c.2194G>A (*6)]. The estimated prevalence of DPYD deficient genotypes in the European population is <8%. This study aimed to determine the prevalence and implication of systematic DPYD testing in an unselected population with GI tumours.
Methods
The germline DPYD test was conducted on a consecutive series of 1000 pts diagnosed with GI malignancies at our Department between June 2020 and December 2022, candidates for FP for colorectal (CRC 69%), gastroesophageal (GEC 15%), biliopancreatic (BPC 12%), other GI tumours (4%) or double GI malignancy (<1%).
Results
Overall, 819 pts (82%) were DPYD wild type (WT) and 181 (18%) had a deleterious DPYD variant. Among DPYD mutated pts, 134 had CRC (74%), 23 GEC (13%), 17 BPC (9%), 5 other GI tumours (2%) and 1 had CRC and GEC (1%). 184 deleterious variants were observed in 181 pts, the most prevalent was DPYD *6 (N=146 15%) (Table). In 4 pts *6 coexisted with other variants, requiring dose personalization. Of 133 pts enrolled in interventional trials including FP treatment, 24 (18%) reported a deleterious variant: 2A N=1, IVS10 N=2, *6 N=21.
Table: 1753P
DPYD status | N= 1000 | % | FP dosea |
DPYD WT | 819 | 82% | 100% |
DPYD6_c2194G>A homozygosis heterozygosis | 146 * 5 141 | 15% | 70% 85% |
IVS10_1129_5923c>G | 20 | 2% | 50-70% |
DPYD2A_1905+1G>A | 12 | 1% | 50% |
DPYD949_c2846A>T | 5 | <1% | 50% |
DPYD13_c1679T>G | 2 | <1% | 50% |
a recommended dose based on SIF and CPIC guidelines *4 patients presented a double heterozygosis DPYD6 and *2A (N=1), FP dose <50% DPYD6 and c*949 (N=1), FP dose <50% DPYD6 and *IVS10 (N=2), FP dose 50%FP= fluoropyrimidines, WT=wild type
Conclusions
Our large cohort of GI pts revealed a higher prevalence of deleterious DPYD variants compared to previous reports. DPYD*6 was the most frequent genotype and, at a low rate, occurred with other variants requiring major dose adjustments. To prevent severe ADR and to adequately report toxicity and changes in pts' quality of life, our data suggest that DPYD assessment should be mandatory and included in all FP-based clinical trials.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale.
Funding
Has not received any funding.
Disclosure
C. Cardone: Financial Interests, Personal and Institutional, Advisory Board: Bayer. All other authors have declared no conflicts of interest.
Resources from the same session
1726P - Optimizing oncology drug spending in a cancer centre in Ireland
Presenter: Ruth Kieran
Session: Poster session 23
1727P - Barriers and facilitators of physician involvement in clinical oncology database management in Ukraine
Presenter: Inesa Huivaniuk
Session: Poster session 23
1728P - Implementation of a comprehensive oncology unit: Needs detected in cancer survivors during follow-up
Presenter: Francisco J Jimenez-ruiz
Session: Poster session 23
1729P - Targeted interventions in registration and reporting of multidisciplinary team meetings (MDT) in oncology help to improve tumor board decisions
Presenter: Lars Galonska
Session: Poster session 23
1730P - Dealing with digital paralysis: Surviving a cyberattack in a cancer centre
Presenter: Rachel J. Keogh
Session: Poster session 23
1731P - Providing access to anticancer drugs within an armed conflict: The experience of Mission Kharkiv (MK) and Medecins Sans Frontieres (MSF) in Ukraine
Presenter: Stanislav Polozov
Session: Poster session 23
1732P - War and the fragility of anticancer drug supply networks in Ukraine
Presenter: Olha Kostenchak-Svystak
Session: Poster session 23
1733P - Two wars at time: Fight against cancer during war time - experience of Ukraine
Presenter: Veronika Patsko
Session: Poster session 23
1734P - Early impact of a personalized lung cancer interception program for heavy smokers
Presenter: Pamela Abdayem
Session: Poster session 23
1735P - Impact of revised US Preventive Services Task Force (USPSTF) 2021 lung cancer screening guideline on long-term cancer survivors in the United States
Presenter: Qian Wang
Session: Poster session 23